• MaaT Pharma will organize a virtual event dedicated to the investment community on the sidelines of the annual meeting of the American Society of Haematology on December 12, 2022.
• Hervé Affagard, CEO, and world-renowned experts will comment on the data presented at the conference, namely the complementary results for 81 patients with acute gastrointestinal graft versus host disease (GI-aGvH) treated with the Microbiome Ecosystem Therapy TM (MET), MaaT013, under the Early Access Program (EAP) and the detailed results of the Phase 1b clinical trial evaluating MaaT033, MET in oral form, in patients with acute myeloid leukemia.
• The Company will also provide a progress report on its development during the event.
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]